PTPRC and neoplasm: ECE treatment promoted a ~3-fold reduction in CD45+CD11b+Ly6C+Ly6G+ neutrophils in 4T1 tumors and >5-fold reduction of these cells in the spleens of 4T1 tumor-bearing mice (Figure 3A,B).